FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Markus Luster

Research Profile

Disorders

Chemicals & Drugs

Procedures

Anatomy

Thyroid Gland

Concepts & Ideas

Physiology

Cell Differentiation

Living Beings

Young Adult

Co-author Network

Publications

TOP 3
F A Verburg; Christoph Reiners; H Barth; M Fassnacht; I Grelle; Markus Luster
Calcium stimulated calcitonin measurement: a procedural proposal.
Frederik A Verburg; Karina Tanase; Elena-Daphne Thies; Andreas K Buck; Stefanie Diessl; Markus Luster; Uwe Mäder; Christoph Reiners
Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients.
Christoph Reiners; Markus Luster
Radiotherapy: radioiodine in thyroid cancer-how to minimize side effects.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Markus Luster (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: F A Verburg; Christoph Reiners; H Barth; M Fassnacht; I Grelle; Markus Luster
Calcium stimulated calcitonin measurement: a procedural proposal.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2013;121(5):318-20.
2013: Frederik A Verburg; Karina Tanase; Elena-Daphne Thies; Andreas K Buck; Stefanie Diessl; Markus Luster; Uwe Mäder; Christoph Reiners
Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients.
The Journal of clinical endocrinology and metabolism 2013;98(1):172-80.
2012: Christoph Reiners; Markus Luster
Radiotherapy: radioiodine in thyroid cancer-how to minimize side effects.
Nature reviews. Clinical oncology 2012;9(8):432-4.
2012: Christoph Reiners; Michael Lassmann; Markus Luster
Recombinant human thyrotropin: safety and quality of life evaluation.
Journal of endocrinological investigation 2012;35(6 Suppl):30-5.
2012: Markus Luster; L S Freudenberg; Heribert Hänscheid; Frederik A Verburg
Radioiodine therapy of metastatic lesions of differentiated thyroid cancer.
Journal of endocrinological investigation 2012;35(6 Suppl):21-9.
2011: Heribert Hänscheid; Andreas K Buck; Guennadi Goulko; Markus Luster; Christoph Reiners; Marcus Schneider-Ludorff; Michael Lassmann
Facing the nuclear threat: thyroid blocking revisited.
The Journal of clinical endocrinology and metabolism 2011;96(11):3511-6.
2011: Christoph Reiners; Heribert Hänscheid; Michael Lassmann; Markus Luster; Frederik A Verburg
Radioiodine for remnant ablation and therapy of metastatic disease.
Nature reviews. Endocrinology 2011;7(10):589-95.
2011: Frederik A Verburg; C Kirchgässner; Helge Hebestreit; Udo Steigerwald; E G W M Lentjes; K Ergezinger; I Grelle; Christoph Reiners; Markus Luster
Reference ranges for analytes of thyroid function in children.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2011;43(6):422-6.
2011: Peter Kletting; Thomas Kull; Markus Luster; Sven N Reske; Donald Bunjes; Gerhard Glatting
Optimal preloading in radioimmunotherapy with anti-cD45 antibody.
Medical physics 2011;38(5):2572-8.
2011: Markus Dietlein; F A Verburg; Markus Luster; Christoph Reiners; F Pitoia; Harald Schicha
One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer.
European journal of nuclear medicine and molecular imaging 2011;38(5):793-8.
2011: Michael Lassmann; Heribert Hänscheid; Frederik A Verburg; Markus Luster
The use of dosimetry in the treatment of differentiated thyroid cancer.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2011;55(2):107-15.
2011: Frederik A Verburg; Michael Lassmann; Uwe Mäder; Markus Luster; Christoph Reiners; Heribert Hänscheid
The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients.
European journal of nuclear medicine and molecular imaging 2011;38(4):673-80.
2010: Stefanie Diessl; Frederik A Verburg; Alexander Hoernlein; Martin Schumann; Markus Luster; Christoph Reiners
Evaluation of an internet-based e-learning module to introduce nuclear medicine to medical students: a feasibility study.
Nuclear medicine communications 2010;31(12):1063-7.
2010: Roland W Freudenmann; Markus Kölle; Axel Huwe; Markus Luster; Sven Norbert Reske; Markus Huber; Peter Lepping; R Christian Wolf; Carlos Schönfeldt-Lecuona
Delusional infestation: neural correlates and antipsychotic therapy investigated by multimodal neuroimaging.
Progress in neuro-psychopharmacology & biological psychiatry 2010;34(7):1215-22.
2010: Markus Luster; Frederik A Verburg; Klemens Scheidhauer
Diagnostic imaging work up in multi-nodular goiter.
Minerva endocrinologica 2010;35(3):153-9.
2010: Michael Lassmann; Christoph Reiners; Markus Luster
Dosimetry and thyroid cancer: the individual dosage of radioiodine.
Endocrine-related cancer 2010;17(3):R161-72.
2010: C Dueren; Markus Dietlein; Markus Luster; F Plenzig; R Steinke; J Grimm; P Groth; W Eichhorn; Christoph Reiners
The use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and implications of daily life.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2010;118(8):513-9.
2010: Daniele Barbaro; Frederik A Verburg; Markus Luster; Christoph Reiners; Domenico Rubello
ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?
European journal of nuclear medicine and molecular imaging 2010;37(7):1251-4.
2010: Frederik A Verburg; Uwe Mäder; Cas L J J Kruitwagen; Markus Luster; Christoph Reiners
A comparison of prognostic classification systems for differentiated thyroid carcinoma.
Clinical endocrinology 2010;72(6):830-8.
2010: Markus Luster; Wolfram Karges; Katrin Zeich; Sandra Pauls; Frederik A Verburg; Henning Dralle; Gerhard Glatting; Andreas K Buck; Christoph Solbach; Bernd Neumaier; Sven N Reske; Felix Mottaghy
Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.
Thyroid : official journal of the American Thyroid Association 2010;20(5):527-33.
2010: Frederik A Verburg; Heribert Hänscheid; Johannes Biko; Maria C Hategan; Michael Lassmann; Michael C Kreissl; Christoph Reiners; Markus Luster
Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.
European journal of nuclear medicine and molecular imaging 2010;37(5):896-903.
2010: Peter Kletting; Thomas Kull; Donald Bunjes; Bettina Mahren; Markus Luster; Sven N Reske; Gerhard Glatting
Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(3):484-91.
2010: Markus Luster; Wolfram Karges; Katrin Zeich; Sandra Pauls; Frederik A Verburg; Henning Dralle; Gerhard Glatting; Andreas K Buck; Christoph Solbach; Bernd Neumaier; Sven N Reske; Felix Mottaghy
Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma.
European journal of nuclear medicine and molecular imaging 2010;37(3):484-93.
2010: Frederik A Verburg; Markus Luster
Low-risk differentiated thyroid carcinoma patients still deserve I-131 remnant ablation after total thyroidectomy.
Minerva chirurgica 2010;65(1):95-100.
2010: Frederik A Verburg; Marcel P M Stokkel; Christian Düren; Robbert B T Verkooijen; Uwe Mäder; Hans VAN ISSELT; Robert J Marlowe; Johannes W Smit; Christoph Reiners; Markus Luster
No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.
European journal of nuclear medicine and molecular imaging 2010;37(2):276-83.
2009: Heribert Hänscheid; Michael Lassmann; Markus Luster; Richard T Kloos; Christoph Reiners
Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.
Endocrine-related cancer 2009;16(4):1283-9.
2009: Rossella Elisei; Martin Schlumberger; A Driedger; Christoph Reiners; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Carine Corone; Eleonora Molinaro; Lucia Grasso; sophie leboulleux; I Rachinsky; Markus Luster; Michael Lassmann; N L Busaidy; Richard L Wahl; Furio Pacini; Steve Y Cho; J Magner; Aldo Pinchera; Paul W Ladenson
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
The Journal of clinical endocrinology and metabolism 2009;94(11):4171-9.
2009: Markus Luster; Daria Handkiewicz-Junak; Armando Grossi; Margaret Zacharin; David Taïeb; Ofelia Cruz; Anne Hitzel; Juan Antonio Vallejo Casas; Uwe Mäder; Massimo E Dottorini
Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study.
The Journal of clinical endocrinology and metabolism 2009;94(10):3948-53.
2009: Frederik A Verburg; Martin Gasser; Matthias Beissert; Eva Geissinger; Markus Luster; Christoph Reiners
Intratracheal growth of recurrent benign goiter.
Thyroid : official journal of the American Thyroid Association 2009;19(9):1009-11.
2009: Patricia Doyle; Christian Düren; Kai Nerlich; Frederik A Verburg; Inge Grelle; Hanne Jahn; Martin Fassnacht; Uwe Mäder; Christoph Reiners; Markus Luster
Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults.
The Journal of clinical endocrinology and metabolism 2009;94(8):2970-4.
2009: Frederik A Verburg; Uwe Mäder; Markus Luster; Christoph Reiners
Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma.
Clinical endocrinology 2009;71(2):291-7.
2009: Frederik A Verburg; Uwe Mäder; Markus Luster; Christoph Reiners
Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases.
European journal of endocrinology / European Federation of Endocrine Societies 2009;160(4):619-24.
2008: Christoph Reiners; Markus Dietlein; Markus Luster
Radio-iodine therapy in differentiated thyroid cancer: indications and procedures.
Best practice & research. Clinical endocrinology & metabolism 2008;22(6):989-1007.
2008: Markus Luster; S E Clarke; Markus Dietlein; Michael Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Guidelines for radioiodine therapy of differentiated thyroid cancer.
European journal of nuclear medicine and molecular imaging 2008;35(10):1941-59.
2007: Lutz S Freudenberg; Walter Jentzen; R J Marlowe; W W Koska; Markus Luster; Andreas Bockisch
124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2007;115(10):690-3.
2007: Markus Luster; Michael Lassmann; Lutz S Freudenberg; Christoph Reiners
Thyroid cancer in childhood: management strategy, including dosimetry and long-term results.
Hormones (Athens, Greece) 2007;6(4):269-78.
2007: Markus Dietlein; J Dressler; Wolfgang Eschner; Frank Grünwald; Michael Lassmann; Bernhard Leisner; Markus Luster; Ernst Moser; Christoph Reiners; Harald Schicha; Otmar Schober
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)].
Nuklearmedizin. Nuclear medicine 2007;46(5):213-9.
2007: Markus Dietlein; J Dressler; Wolfgang Eschner; Frank Grünwald; Michael Lassmann; Bernhard Leisner; Markus Luster; Christoph Reiners; Harald Schicha; Otmar Schober
[Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3)].
Nuklearmedizin. Nuclear medicine 2007;46(5):206-12.
2007: P Andermann; S Schlögl; Uwe Mäder; Markus Luster; Michael Lassmann; Christoph Reiners
Intra- and interobserver variability of thyroid volume measurements in healthy adults by 2D versus 3D ultrasound.
Nuklearmedizin. Nuclear medicine 2007;46(1):1-7.
2006: Heribert Hänscheid; Michael Lassmann; Markus Luster; Stephen R Thomas; Furio Pacini; Claudia Ceccarelli; Paul W Ladenson; Richard L Wahl; Martin Schlumberger; Marcel Ricard; Al Driedger; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Vincent Carriere; Carine Corone; Christoph Reiners
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(4):648-54.
2006: PAMELA SCHROEDER; Bryan R Haugen; Furio Pacini; Christoph Reiners; Martin Schlumberger; Steven I Sherman; David S Cooper; Kathryn G Schuff; Lewis E Braverman; Monica C Skarulis; terry Davies; Ernest L Mazzaferri; Gilbert H Daniels; Douglas S Ross; Markus Luster; Mary H Samuels; Bruce D Weintraub; E Chester Ridgway; Paul W Ladenson
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal.
The Journal of clinical endocrinology and metabolism 2006;91(3):878-84.
2006: Furio Pacini; Paul W Ladenson; Martin Schlumberger; A Driedger; Markus Luster; Richard T Kloos; S Sherman; Bryan R Haugen; Carine Corone; Eleonora Molinaro; Rossella Elisei; Claudia Ceccarelli; Aldo Pinchera; Richard L Wahl; sophie leboulleux; Marcel Ricard; J Yoo; N L Busaidy; E Delpassand; H Hanscheid; R Felbinger; Michael Lassmann; Christoph Reiners
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.
The Journal of clinical endocrinology and metabolism 2006;91(3):926-32.
2006: Markus Luster
Acta Oncologica Lecture. Present status of the use of recombinant human TSH in thyroid cancer management.
Acta oncologica (Stockholm, Sweden) 2006;45(8):1018-30.
2006: S Schlögl; P Andermann; Markus Luster; Christoph Reiners; Michael Lassmann
A novel thyroid phantom for ultrasound volumetry: determination of intraobserver and interobserver variability.
Thyroid : official journal of the American Thyroid Association 2006;16(1):41-6.
2005: Markus Luster; Ralph Felbinger; Markus Dietlein; Christoph Reiners
Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration.
Thyroid : official journal of the American Thyroid Association 2005;15(10):1147-55.
2005: Michael Lassmann; Markus Luster; Heribert Hänscheid; Christoph Reiners
Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(5):899.
2005: Markus Luster; Francesco Lippi; Barbara Jarzab; Petros Perros; Michael Lassmann; Christoph Reiners; Furio Pacini
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Endocrine-related cancer 2005;12(1):49-64.
2004: Sarah Kaufmann; Cornelia Schmutzler; Lutz Schomburg; Carsten Körber; Markus Luster; Johann Rendl; Christoph Reiners; Josef Köhrle
Real time RT-PCR analysis of thyroglobulin mRNA in peripheral blood in patients with congenital athyreosis and with differentiated thyroid carcinoma after stimulation with recombinant human thyrotropin.
Endocrine regulations 2004;38(2):41-9.
2004: Michael Lassmann; Markus Luster; Heribert Hänscheid; Christoph Reiners
Impact of 131I diagnostic activities on the biokinetics of thyroid remnants.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2004;45(4):619-25.
2004: Jamshid Farahati; Markus Geling; Uwe Mäder; Markus Mörtl; Markus Luster; Justus G Müller; Michael Flentje; Christoph Reiners
Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1981-1995.
Thyroid : official journal of the American Thyroid Association 2004;14(2):141-7.
2003: Markus Luster; Steven I Sherman; Monica C Skarulis; James R Reynolds; Michael Lassmann; Heribert Hänscheid; Christoph Reiners
Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
European journal of nuclear medicine and molecular imaging 2003;30(10):1371-7.
2002: Stephan Timm; Wulf Hamelmann; Markus Luster; Christoph Reiners; Markus Geling; Arnulf Thiede; Wolfgang Timmermann
[Patient selection criteria for single-sided or minimal invasive operative procedures in primary hyperparathyroidism (pHPT)].
Zentralblatt für Chirurgie 2002;127(5):443-7.
2000: Markus Luster; Michael Lassmann; H Haenscheid; U Michalowski; C Incerti; Christoph Reiners
Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
The Journal of clinical endocrinology and metabolism 2000;85(10):3640-5.
2000: Markus Luster; Walter Reinhardt; C Korber; Michael Lassmann; H Haenscheid; U Michalowski; Johann Rendl; E Eising; K Mann; Christoph Reiners
The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production.
Journal of endocrinological investigation 2000;23(7):473-5.
1999: Bryan R Haugen; Furio Pacini; Christoph Reiners; Martin Schlumberger; Paul W Ladenson; Steven I Sherman; David S Cooper; KE Graham; Lewis E Braverman; Monica C Skarulis; terry Davies; L J DeGroot; Ernest L Mazzaferri; Gilbert H Daniels; Douglas S Ross; Markus Luster; Mary H Samuels; D V Becker; Harry R Maxon; R R Cavalieri; CA Spencer; K McEllin; Bruce D Weintraub; E Chester Ridgway
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
The Journal of clinical endocrinology and metabolism 1999;84(11):3877-85.
1999: Christoph Reiners; Markus Luster; Michael Lassmann
Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131.
Journal of endocrinological investigation 1999;22(11 Suppl):17-24.
1998: Walter Reinhardt; Markus Luster; Karl-Heinz Rudorff; Christian Heckmann; S Petrasch; Sebastian Lederbogen; R Haase; Bernhard Saller; Christoph Reiners; D Reinwein; Klaus Mann
Effect of small doses of iodine on thyroid function in patients with Hashimoto's thyroiditis residing in an area of mild iodine deficiency.
European journal of endocrinology / European Federation of Endocrine Societies 1998;139(1):23-8.